Validation of Pegasus-OCT, an artificial intelligence based software for the automated detection of macula disease from OCT scans, is conducted on independent, multi-centre data. 5,588 volumes spanning multiple populations, device manufacturers and acquisition sites were assessed. Pegasus-OCT achieves AUROCs of >98% on AMD, DME and general anomaly detection.
Introduction
More than 250 million people globally are currently estimated to be living with moderate to severe visual impairment or blindness 1 . That figure is predicted to double by 2040 due to the projected increase in population growth and ageing 2 . This places a significant burden on healthcare services. Despite there being over 200,000 ophthalmologists worldwide, there is currently a significant shortfall of practitioners in developing countries. Furthermore, although the number of ophthalmologists is increasing in developed countries, the population aged above 60 years is growing at twice the rate of the profession 3 . Prompt and substantive steps are therefore needed to alleviate the current and anticipated deficit of expertise.
Diseases of the macula such as age-related macular degeneration (AMD) and diabetic macular edema (DME) constitute some of the main causes of avoidable sight loss in developed nations.
The prevalence of AMD, for instance, was 170 million people in 2016 4 , projected to increase to 196 million in 2020, and further to 288 million by 2040 5 . These diseases manifest as anatomical changes to the macula such as the development of drusen, retinal pigment epithelium detachments, and the build up of subretinal and/or intraretinal fluid. The identification of these characteristics is crucial to both detection and to treatment management 6, 7, 8 .
Optical coherence tomography (OCT) imaging is currently the most frequently used imaging modality in the evaluation of macular disease, with over 30 million scans taken per year 9 . For the diagnosis of AMD, a 70-fold increase in the use of OCT has been recorded since its introduction 10 and it has additionally become a critical tool for the baseline retinal evaluation needed to guide administration of therapy 11, 12 .
OCT imaging is now widely regarded as the gold standard for guiding the diagnosis and treatment of AMD and DME. However, the resulting rapid expansion in imaging data generated has not been matched by the availability of trained experts to interpret these scans accurately.
Computer-aided diagnosis (CAD) has the potential to alleviate the human and economic burden of disease detection. Recently, CAD systems that utilise Artificial Intelligence (AI) in particular have gained prominence, for instance in the detection of Diabetic Retinopathy (DR) from fundus photographs 13, 14 . However, the use of AI CAD systems for the analysis of OCT image data has so far been less explored.
The applicability of AI in ophthalmic diagnosis has become particularly propitious since the development of a method known as deep learning 15, 16 . Deep learning uses convolutional neural networks to process grid-based data such as images, and has been observed to be particularly successful in automated imaging diagnostics 17 . A deep learning algorithm aims to mimic the way the human expertise is developed for the same task by discovering image features that distinguish normal from pathological classes. These features are then used to classify new images when the algorithm is applied. However, a potential risk is that poor or unexpected performance may occur if the data used to train the algorithm inadequately captures the diversity of patients and images present in real world scenarios 18 . While humans can generalise knowledge learned on one set of images to others which may have very different appearances, deep learning algorithms are prone to overfitting or bias resulting from limited variation in training data 19 . A thorough evaluation of any algorithm is therefore necessary before adoption in clinical practice.
In the interpretation of ophthalmic images using deep learning, the largest body of work to date has been in the detection of DR from fundus photographs 20, 21, 22, 23 . The use of these methods in clinical practice has also been shown in retrospective trials to provide significant reduction in the manual burden and costs of screening for DR 24, 25 . Although research in OCT analysis is more incipient, papers released in recent years have shown promising results 26, 27, 28, 29, 30 .
The largest scale prior investigations 28, 29, 30 evaluate their algorithms on 1000-2151 OCT volumes. However, common to all the above algorithms is a concern that results are presented on evaluation sets which are from the same cohorts as those that the algorithms were trained on. Questions therefore remain as to how these algorithms would perform on examples from cohorts external to the training set 18 . To date, none of the algorithms in the papers described above have been made available by their authors for external evaluation.
In the case of OCT it has been shown that, even in the absence of disease, variations in ethnicity, age and gender can result in statistically significant differences in the appearance of retinal structures 31, 32 . In addition, imaging variation due to the acquisition device needs to be accounted for.
This paper provides an evaluation of Pegasus-OCT, a commercial AI based system for the detection of retinal diseases from OCT images of the macula. In contrast to prior work in the field, the evaluation is conducted on independent datasets spanning a range of acquisition sites and scanner types, on a total of 5,588 OCT cube volumes (162,721 B-scans). To the best of our knowledge, it represents the first evaluation of deep learning based algorithms for OCT image interpretation on data originating from populations that have not in any way been utilised in creating the algorithms.
Methods

Automated Disease Detection
Pegasus-OCT v1.0 is a clinical decision support system for detecting disease from OCT scans The detection of drusen may therefore result in a high score for both of these categories if other features of Wet AMD (such as fluid) are also present. An additional classification of General AMD, obtained by pooling Wet and Dry predictions, is therefore also presented in this paper.
Deep Learning Models
The four classifiers used are all binary classifiers which utilise the same VGG16 convolutional neural network model 34 . Details of the network architecture and training details are given in Supplemental Digital Content 1. These models have been trained on OCT data acquired from different manufacturers and using a range of imaging protocols. Before training, all images are normalised to have the same size and intensity range. In addition, to increase generalisability, significant image augmentation is used during training. At each training epoch, images are read in with a random rotation, translation, zoom and brightness enhancements applied. This means that the model never sees the same image twice during training and serves to enlarge the range of training data. Finally, to prevent overfitting to the training data, early stopping is used 19 . These extensions enable the application of the classifiers to images acquired from different scanners and with differing B-scan resolutions.
Image Quality Assessment
An automated strategy for disease detection requires images of sufficient quality to reliably visualise retinal anatomy. Poor contrast, extensive noise, or artifacts may conceal the presence of real pathology or may be confused for abnormalities in otherwise normal scans. We therefore also verify the quality of each B-scan in terms of suitability for automated disease detection. This is done via a deep learning method which classifies scans as being either 'gradable' or 'ungradable'. An overall quality rating is then reported for each dataset, reflecting the percentage of gradable B-scans in the dataset.
Performance Evaluation
In this paper, the results of Pegasus-OCT in classifying each of the four categories are evaluated on five external datasets. These datasets were acquired independently of the Pegasus-OCT manufacturer as well as independently of each other. Local ethical committee approval was obtained for each dataset where required. The datasets span geographic locations and multiple acquisition sites, and were acquired with a range of protocols and scanners. A summary of the datasets used in the evaluation of Pegasus-OCT is shown in Table   1 . Where available, demographic information is given in Supplemental Digital Content 2. An example image from each dataset can be seen in Figure 1 .
Images from these datasets were run through the Pegasus-OCT software with the operator masked to ground truth diagnoses. The results of Pegasus-OCT were then compared to the provided ground truth at a whole volume level. However, for dataset A1, whole macular volumes were not made available for assessment. Instead, ground truth is provided for each individual B-scan in the dataset and so the results are assessed at a B-scan level in this case only.
All classifiers are run on all images which report a probability of anomaly or pathology for each of the four cases. The classification of General Anomaly is based solely on the probability of this classifier exceeding a specified threshold, where the same threshold is applied across all datasets. For the pathology classes, if only one classifier yields a probability above the relevant threshold, the subject is classified with that pathology. However there are cases in which two or more classifiers report probabilities above the required threshold. In the case of Wet and Dry AMD being present, the volume will always be classified as Wet AMD. Where both AMD and DME are present, the classification will be assigned to that with the highest probability. It should be noted that while this allows quantitative evaluation of the algorithms, having all probabilities available to a user in a clinical setting may be helpful in the assessment of complex cases.
The performance of Pegasus-OCT was evaluated by calculating the area under the curve of the receiver operating characteristic (AUROC) curves as in comparable work 28, 29, 30 . The AUROC is a measure of the diagnostic ability of a predictor in a binary classification. It gives the probability that the classifier will rank a randomly chosen pathological instance higher than a randomly chosen instance without that pathology. SDOCT study recruited AMD subjects from the AREDS 2 study population at 4 AREDS 2 Study
Datasets from Public Sources
Centers. Controls were recruited from Duke University Eye Center and Emory University.
Subjects included were AMD subjects and controls, men and women between the ages of 50 and 85 years. The AMD subjects had macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye. Subjects were excluded only if the ocular media was not clear enough to allow good fundus photography.
Dataset A3 36 consists of 148 cases with a distribution of 50 normal controls, 48 Dry AMD, and 50 DME, acquired at Noor Eye Hospital in Tehran on Heidelberg SD-OCT imaging systems.
These data contains varying number of both A-scans (512 or 768) and B-scans (range 19-61).
No further demographic information is available.
Datasets from Private Sources
Dataset B1 consists of 25 DME, 25 Dry AMD, 25 Wet AMD, and 25 normal controls, imaged on 
Results
Results of the evaluation of Pegasus-OCT on all datasets are shown in Table 2 . The Quality
Rating is an automated assessment of the percentage of B-scans in each dataset deemed to be of sufficient quality for automated grading. The same threshold for quality was used across all datasets.
For the purposes of this paper, evaluation was conducted on all images regardless of quality.
Accuracy, sensitivity, specificity and AUROC results were reported at a whole macular volume level, using ground truth provided by the dataset owners. For dataset A1 only, volume-level labels were not available. However, all 108,309 B-scans were individually labelled by the providers, and so the metrics are evaluated on a B-scan level in this case. All accuracy, sensitivity and specificity results have been reported at the same threshold on the ROC curve for all datasets. Actual ROC curves can be found in Supplemental Digital Content 3.
In distinguishing between normal and abnormal scans, Pegasus-OCT performs at an AUROC of over 98% for every dataset. In datasets with quality ratings of above 50%, the minimum AUROCs obtained for the detection of general AMD and DME were found to be 99% and 98%, respectively. Lower performance was observed when the image quality of the B-scans was deemed to be insufficient for automated grading. It should be noted that ground truth for datasets such as B2 were obtained using clinical information in addition to the OCT volume presented.
Discussion
Clinical decision support systems for the analysis of macula OCT scans offer substantial promise. Such systems can be agile and their performance adjusted for the specific integration in workflow. For example, in a screening context, specificity could be increased to avoid unnecessary false positives which can burden secondary care 25 . Similarly they have the potential to be deployed at scale and therefore at low cost, thus benefiting healthcare providers 24 .
Crucial to the translation of algorithms from theory to the clinic is the idea of generalisability. An algorithm needs to perform well on data acquired from a variety of populations, devices, operators and protocols. The power of deep learning algorithms lies in their flexibility and capacity to encode very large and complex amounts of information. However, this also makes deep learning algorithms particularly vulnerable to bias stemming from the data they are trained on (overfitting), which can result in catastrophic failures when applied in the real world 18, 37 .
Despite this, even the most notable publications have only evaluated their algorithms on subjects from the same populations as those on which they were trained. While providing promising preliminary results, the extrapolation of the stated performance of these algorithms to more diverse data sources cannot -and must not -be assumed.
In contrast, this paper conducts an evaluation of Pegasus-OCT on purely external datasets, which were not used in the creation of the algorithms. It represents validation of an AI system on the largest and most diverse OCT data to date, to the best of our knowledge, with data acquired from multiple sites in five different countries analysed. The heterogeneity of the datasets used aims to address any potential selection biases. A comparison of the evaluation datasets used in the work presented here and in pertinent prior work is shown in Table 3 .
The results show promising performance of Pegasus-OCT. Evaluation has been conducted on large datasets from multiethnic populations, without any specific optimisation. Accuracy, sensitivity and specificity analysis was conducted at a common threshold on the ROC curve across all datasets. Improved performance is likely to be obtained when the cut-off point on the ROC curve is chosen specifically to optimise the characteristics of a particular clinical site.
These results presented in this paper are comparable to those of prior related work in Table 3 .
In the separation of Normal and AMD patients, an AUROC of 93.8% for classification of macula cube volumes and 97.5% when multiple volumes from the same patient were combined for an overall diagnosis was reported 28 . Dataset A1 was used to distinguish between urgent referrals and observation cases with a resulting AUROC of 99.9% 29 . Most recent work 30 reported
AUROCs for disease detection of 99.5% and individual pathology detection ranges between 96.6% to 100%. The key difference is that these papers use between 80-99% of their cohort data to train their algorithms, with the evaluation conducted on the remaining subjects in the cohort.
While the results presented in this paper have been evaluated on data from a range of external sources, the distribution of scanner manufacturer used is still unbalanced. The majority of data have been evaluated on Heidelberg scanners which also show the best performance. However, these datasets were also assessed to have the highest quality scans. Further work is needed to disambiguate the influence of scanner manufacturer and image quality in the performance of Pegasus-OCT.
The study presented evaluated defined datasets including normal, wet, dry AMD and DME.
Other disease types, such as Macular/Lamellar Hole, Epiretinal Membrane (ERM) were not explicitly labelled in the datasets and so were not independently assessed in this version of the platform. However signs of these may have been present in images of other pathology (such as Dry AMD with ERM).
As the datasets were mainly taken from trials or secondary care, the prevalence of the diseases evaluated in this paper are likely to be lower and milder in a screening setting. However, by adjusting sensitivity and specificity thresholds, performance can be tailored to suit the intended use of the software. This opens up exciting and transformative opportunities to utilise OCT in non-specialist settings, with subsequent work required to determine the health economic effects of such system implementation. Furthermore, the use of such commercially available platforms has the potential to assist clinicians in managing the exponential demand in eye care services caused by retinal disease. None of the images in these datasets were used in the development of Pegasus-OCT. 
